Blood flow restriction ahead of surgery could be key.

A San Antonio researcher hopes to dispel myths about who is at risk for eating disorders while studying the interaction between binge eating disorder and food insecurity in older Hispanic women.

David Morilak, PhD, a professor of pharmacology and director of the Center for Biomedical Neuroscience at UT Health San Antonio, studies rats in an effort to understand the characteristics of stressful events that can lead to PTSD in humans.

A cutting-edge technology and an exciting recent hire hint at exciting developments in the future of precision medicine in the diagnosis and treatment of Alzheimer's disease.

Adam Salmon, PhD, studies aging in marmosets. He and his team recently concluded that an immunosuppressant called rapamycin extends the lifespan of marmosets. This has significant implications for the study of aging in humans.

A medication that appears to preserve brain function after a stroke will soon go into human trials. The San Antonio researcher who discovered the medication's potential more than two decades ago is still leading the team.

People with concussions get checked out pretty thoroughly by their doctors, but for some, there are cognitive changes and deficits that doctors don’t pick up.

Oral squamous cell carcinoma kills about half of the people who get it, and there have been no new treatments developed for half a century. A UT Health San Antonio dentist has developed a novel drug that may offer these patients a better chance at survival.

Pelvic health disorders can disrupt women's quality of life. The conditions might be considered common and inevitable, but they should not be ignored.

A San Antonio researcher is working on a drug that could treat Ewing sarcoma and rhabdomyosarcoma without lifelong side effects. It would be the first new treatment option for these childhood cancers in 30 years.

More than six-million American adults are experiencing heart failure right now.

A new technique for delivering radiation to glioblastoma brain tumors may allow doctors to use much higher doses while preserving healthy brain tissue. UT Health San Antonio's Andrew Brenner, MD, PhD, says this may give patients more time.